BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Real-time BOERSE MUENCHEN 01:16:21 15/06/2024 am IST | ||
| 1,037 EUR | +0.33% |
|
| Current month | +7.34% | ||
| 1 month | +15.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 1,037 | +0.33% |
| 13/24/13 | 1,033 | +1.19% |
| 12/24/12 | 1,021 | +0.23% |
| 11/24/11 | 1,019 | -0.19% |
| 10/24/10 | 1,021 | +1.17% |
Real-time BOERSE MUENCHEN
Last update June 15, 2024 at 01:16 am IST
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD52AR |
| ISIN | DE000HD52AR9 |
| Date issued | 26/04/2024 |
| Strike | 1,200 $ |
| Maturity | 20/06/2025 (369 Days) |
| Parity | 1 : 1 |
| Emission price | 824 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,043 € |
|---|---|
| Lowest since issue | 815.1 € |
| Spread | 0.22 € |
| Spread % | 0.02% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Certificates
- Certificat
